China’s CDE Accepts IND Application for Boan Biotech’s BA1203 (A Masked Anti-PD-1/IL-2 Fusion Protein)

Boan Biotech announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for ...

VOLUNTARY ANNOUNCEMENT CDE ACCEPTANCE OF IND APPLICATION FOR BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2026

Boan Biotech Receives CDE Clearance for Phase Ⅱ Clinical Trial of BA1106 in Combination with BA1104 for NSCLC

Yantai, July 2, 2026 –- Boan Biotech announced today that China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has cleared the company’s ap...

VOLUNTARY ANNOUNCEMENT CDE APPROVAL OF PHASE II CLINICAL TRIAL APPLICATION FOR BA1106 IN COMBINATION WITH BA1104 FOR NSCLC

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 JUNE 2026

VOLUNTARY ANNOUNCEMENT LICENSING OF DULAGLUTIDE INJECTION IN THE U.S.

Boan Biotech Out-licenses Its Dulaglutide Injection in the U.S.

Yantai, June 4, 2026 -- Boan Biotech announced that it has entered into a licensing agreement for the United States rights of BA5101 (Dulaglutide Injection). Under the agreement, the partner will comm...

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026

Boan Biotech Presents Updated Phase I Clinical Data for BA1301 (Anti-CLDN18.2 ADC) at the 2026 ASCO Annual Meeting

Yantai, China, May 30, 2026 -- Boan Biotech today presented the updated data of a Phase I clinical trial for its BA1301, an investigational antibody-drug conjugate (ADC) targeting CLDN18.2, at the 202...